Nithya Jesuraj, Hannah Senior, Shaya Anderson, Joy Aho, Sean Kevlahan
The recent success of immune cell therapy has driven an increased focus on manufacturing optimization. Efficiently generating a sufficient number of CAR T, or other T cells, for a therapeutic dose is a critical improvement needed for successful cell therapy manufacturing. Cell activation technologies, cytokine dosing schedules, and easy-to-use bioreactor platforms are key parameters for optimizing this process. In this study, we investigate the compatibility and efficiency of ex vivo T cell expansion from human peripheral blood mononuclear cells (PBMCs) using the novel Cloudz™ CD3/CD28 dissolvable polymer microparticles in combination with the G-Rex® bioreactor system and varying dose schedules of IL-2. Additionally, cells were cultured in serum-free media conditions after determining the best seeding density, and cytokine dosing schedule.